Table 2.
Adjusted odds ratios for receipt of concurrent CRT versus any other treatment a
| Characteristic | Estimate | 95% Confidence Limits | |
|---|---|---|---|
| Patient-related | Lower | Upper | |
| Female | 0.64 | 0.40 | 1.03 |
| White | 1.24 | 1.004 | 1.53 |
| Hispanic | 0.71 | 0.39 | 1.31 |
| Married | 1.13 | 0.96 | 1.33 |
| Medicare enrollment any time between 2013 and 2017 | 1.13 | 0.89 | 1.43 |
| Medicaid-eligible | 0.63 | 0.34 | 1.14 |
| Priority status (reference: non-service connected) | |||
| Service connected ≥50% | 1.12 | 0.94 | 1.33 |
| Service connected < 50% | 1.01 | 0.81 | 1.27 |
| Urban residence | 1.09 | 0.91 | 1.33 |
| Histology (reference: squamous) | |||
| Adenocarcinoma | 0.91 | 0.77 | 1.07 |
| Other | 0.80 | 0.62 | 1.02 |
| Smoking status (reference: never) | |||
| Current smoker | 1.41 | 0.90 | 2.20 |
| Former smoker | 1.34 | 0.85 | 2.10 |
| Unknown | 1.13 | 0.65 | 1.95 |
| Diagnosis year (reference: 2013) | |||
| 2017 | 1.65 | 1.27 | 2.16 |
| 2016 | 1.36 | 1.06 | 1.76 |
| 2015 | 1.11 | 0.88 | 1.39 |
| 2014 | 1.22 | 0.98 | 1.53 |
| Age (increment = 10) | 0.67 | 0.60 | 0.76 |
| Charlson-Deyo comorbidity score (increment = 1) | 0.94 | 0.91 | 0.97 |
| Distance between patient residence and medical center based on zip code (increment = 100 miles) | 0.95 | 0.84 | 1.08 |
| Medical center-related | |||
| Geographic (Census) region (reference: South) | |||
| Northeast | 1.01 | 0.66 | 1.55 |
| Midwest | 1.19 | 0.82 | 1.73 |
| West | 0.89 | 0.60 | 1.33 |
| Medical Center Certified by Commission on Cancer | 0.93 | 0.68 | 1.27 |
| Total number of unique patients seen at oncology clinics at medical center of diagnosis during diagnosis year (increment = 100) | 1.03 | 0.92 | 1.15 |
| Total number of oncologists at medical center of diagnosis (increment = 10) | 0.93 | 0.70 | 1.22 |
aFinal model based on 3093 patients who had no missing data across variables. Those from Puerto Rico were excluded due to small sample size